

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **CSPC PHARMACEUTICAL GROUP LIMITED**

**石藥集團有限公司**

*(Incorporated in Hong Kong with limited liability)*

**(Stock Code: 1093)**

### **APPOINTMENT OF AN EXECUTIVE DIRECTOR**

The Board of Directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that with effect from 21 November 2025, Mr. QU Zhiyong (“**Mr. QU**”) has been appointed as an Executive Director of the Company.

Set out below are the biographical details of Mr. QU:

Mr. QU, aged 44, who joined the Group in July 2004, is currently the General Manager of the Group’s Hong Kong Head Office Management Centre and a Director of the Group’s Finance Centre, primarily responsible for the financial affairs of the Group. He is also a director of certain subsidiaries of the Company, and previously served as Finance Director of the Group’s Investment and Financing Division. Mr. QU holds a Bachelor’s degree in Business Administration from the Hefei University of Technology.

Mr. QU is a director of Common Success International Limited, a substantial shareholder of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**SFO**”).

The Company has entered into a service contract with Mr. QU for a term of three years, and he is subject to retirement and re-election at the annual general meeting of the Company in accordance with the articles of association of the Company. Mr. QU is entitled to receive a monthly salary of RMB60,000 and an annual director’s fee of HK\$63,000 under his service contract. In addition, he is also eligible to receive performance-related discretionary bonus to be determined by the Board. His emoluments were determined by the Board based on the recommendations of the remuneration committee and with reference to his experience, responsibilities with the Company, current market practices and the remuneration policy of the Company.

As at the date of this announcement, Mr. QU has personal interests in (1) 90,000 shares of the Company; (2) unvested share awards of 700,000 shares of the Company granted by Key Honesty Limited, a shareholder of the Company which is wholly owned by Mr. CAI Dong Chen, a substantial shareholder of the Company within the meaning of Part XV of the SFO; (3) and 800 shares of CSPC Innovation Pharmaceutical Co., Ltd., an indirect non-wholly owned subsidiary of the Company whose shares are listed on the ChiNext of Shenzhen Stock Exchange (Stock Code: 300765) and an associated corporation of the Company within the meaning of Part XV of the SFO.

Save as disclosed above, Mr. QU does not have any relationship with any director, senior management, substantial or controlling shareholder of the Company with the meaning ascribed to them under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”), and has not held any directorships in any other publicly listed companies in Hong Kong or overseas in the past three years.

Save as disclosed in this announcement, Mr. QU confirmed that there is no other information that needs to be disclosed pursuant to Rule 13.51(2) of the Listing Rules, and there are no other matters concerning his appointment that need to be brought to the attention of the shareholders of the Company.

The Board would like to extend a warm welcome to Mr. QU on his appointment.

By order of the Board  
**CSPC Pharmaceutical Group Limited**  
**CAI Dong Chen**  
*Chairman*

Hong Kong, 21 November 2025

*As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin, Mr. CHEN Weiping and Mr. QU Zhiyong as Executive Directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as Independent Non-executive Directors.*